Skip to main content
Figure 6 | BMC Cancer

Figure 6

From: Human papillomavirus (HPV) type 16 E7 protein bodies cause tumour regression in mice

Figure 6

Ex vivo IFN-γ, CTL activity and Granzyme B ELISPOT responses in mice inoculated with Zera® separately. Two groups of four mice were immunized with 100 μg DNA vaccine, or 2.5 μg 16E7SH +/- 2.5 μg Zera® PBs +/- 100 μl IFA per animal for each assay. (A) Ex vivo IFN-γ ELISPOT responses. Given are the means of IFN-γ secreting cells/104 splenocytes ± SEM. (B) Ex vivo Granzyme B ELISPOT responses. Four mice per group were immunized with 5 μg protein injected per animal. Given are the means of Granzyme B-secreting cells / 104 splenocytes ± SEM. 16E7SH protein compared to 16E7SH protein plus Zera® PBs (Exp. I - p = 0.0001, Exp. II p < 0.05). (C) The splenocytes were tested by 51Cr-release assays after one round of in vitro restimulation for lysis of syngeneic E7-wildtype expressing 2 F11 target cells. Data gives the mean ± SEM of the indicated group (n = 4). One representative of the two experiments is shown.

Back to article page